BMC’s Yawkey building doors are now closed as an entrance as part of our ongoing efforts to enhance our campus and provide you with the best clinical care.

All patients and visitors on our main campus must enter our hospital via Shapiro, Menino, or Moakley buildings, where they will be greeted by team members at a new centralized check-in desk before continuing to the hospital. We are excited to welcome you and appreciate your patience as we improve our facilities.


Fabio Petrocca, MD, is an oncologist at Boston Medical Center (BMC), where he is also Director of the CAR T-cell Therapy Program. Dr. Petrocca is also an assistant professor of Medicine and Director of the Cellular Therapy Program at Boston University Chobanian & Avedisian School of Medicine. He is a physician-scientist focused on treating benign and malignant hematologic conditions, including lymphomas, leukemias, and multiple myeloma. His research focuses on the development of immune effector cell therapies for cancer and enabling equitable patient access to innovative and powerful cancer cell therapies such as CAR T. After completing his medical degree and oncology training in Italy, Dr. Petrocca completed a research fellowship at the Program in Cellular and Molecular Medicine at Harvard Medical School. He has been practicing for more than 15 years.

  • Specialties

    Hematologic malignancies, lymphomas, leukemias, multiple myeloma

  • Languages

  • Pronouns

  • Administrative Title

    Director, Cellular Therapy Program and Assistant Professor of Medicine, Boston University Chobanian and Avedisian School of Medicine

  • Residency

    Oncology, University of Ferrara, Italy, 2004-2008
  • Fellowship

    Research Fellowship, Program in Cellular and Molecular Medicine, Harvard Medical School, 2008-2012
  • Education

    University of Rome, Sapienza, Italy, 2004
  • Board Certifications

    Oncology (Italy)

My Publications

  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
  2. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
  3. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

    BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment.
  4. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

    Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. In this case report, we detail the successful treatment of a relapsed and refractory multiple myeloma (MM) patient treated with an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy immediately following clinical recovery from COVID-19.